Compound ID | 2896
Class: Pleuromutilin
Spectrum of activity: | Gram-positive |
Details of activity: | Active against Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus faecalis, vancomycin-resistant Enterococcus faecium |
Propensity to select resistant mutants: | Yes, at 6 to 4.4 x 10^9 mutation frequency at 4xMIC |
Description: | Semisynthetic compound with triaromatic C22-conjugated pleuromutilin scaffold; efficacious in reducing Staphylococcus aureus burden in a mouse infection model; oral solution and current form (2 HCl) makes bioavailability of compound unfavourable (likely poor intestinal solubility or high metabolism in mice and pigs); derivatives reported |
Institute where first reported: | Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, DK-5230 Odense M, Denmark |
Year first mentioned: | 2024 |
Development status: | Experimental |
Chemical structure(s): | |||||||||||
|
|
External links: | |
PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/168841449 |
Guide to Pharmacology: | compound 16 [PMID: 38385364] |
Citation: | https://pubs.acs.org/doi/10.1021/acs.jmedchem.3c02153 |